Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Phase 2 Completed 60 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2010-12
Primary completion: 2014-07
Completion: 2015-08

Publications

Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015 Nov;171(4):463-70. doi: 10.1111/bjh.13603. Epub 2015 Jul 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-2206	Small molecule	135 mg	Oral
Subject	MK-2206	Small molecule	200 mg	Oral
Subject	MK-2206	Small molecule	250 mg	Oral
Subject	MK-2206	Small molecule	300 mg	Oral

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Summary

Timeline

Publications

Drugs

Indications